Precision drug development*
Endocyte is currently sponsoring a clinical trial related to an oncology product candidate.
Endocyte has sponsored a new global phase 3 clinical research study in men with progressive metastatic castration-resistant prostate cancer (mCRPC), called the VISION study, will evaluate the effectiveness and safety of the investigational drug 177Lu-PSMA-617 in combination with the best standard of care versus patients treated with best standard of care.
For more information
Medical professionals requesting additional information may contact firstname.lastname@example.org
* The safety and efficacy of these agents have not been established. There is no guarantee that the agents will receive regulatory approval and become commercially available for the uses being investigated.